Condition
Alzheimer Type Dementia
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 3 (2)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06898424Not ApplicableCompletedPrimary
Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression
NCT07251023Phase 3RecruitingPrimary
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
NCT01245530Phase 3CompletedPrimary
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
Showing all 3 trials